PMA Supplement Types Explained: 180-Day, Panel-Track, Real-Time, 30-Day, and Special

A Premarket Approval (PMA) is not a one-time event. Once a Class III device is approved, almost everything a manufacturer does to evolve it — a new software revision, a sterilization site move, an expanded indication, a label tweak — is implemented through a PMA supplement. (Note the distinction: a supplement changes an already-approved PMA, whereas a PMA amendment is a change to an application that is still under FDA review. This article covers post-approval supplements.) Choosing the wrong supplement type is one of the most expensive regulatory mistakes a Class III team can make: it either delays a launch while FDA re-reviews, or it draws a finding for implementing a change without the right submission. This article explains the supplement types under 21 CFR 814.39, when each applies, and what real-world change data reveals about how manufacturers actually use them.

Why Supplement Type Decides Your Timeline

The supplement type determines three things at once: how much data you must generate, how long FDA will take, and whether you can ship before approval. A 30-day notice lets a manufacturer distribute 30 days after FDA receives it (unless FDA objects); a 180-day or panel-track supplement can require new clinical data and an advisory committee before a single unit ships. Getting the classification right up front — using 21 CFR 814.39 and the FDA's "Modifications to Devices Subject to PMA" guidance — is therefore a scheduling decision, not just a paperwork one.

The Scale of Supplementing, and Why It Maps to Supplement Type

Supplements dwarf original approvals: roughly 97% of records in the FDA's public PMA database are supplements, and only about 3% are original PMA approvals, with the agency acting on a few thousand supplements every year. The work is also concentrated — cardiovascular and neuromodulation franchises (Medtronic, Boston Scientific, Abbott) accrue hundreds of supplements per device over decades as implants are continuously refined. (For the full record counts, applicant concentration, advisory-committee mix, and year-over-year trends, see our PMA Class III landscape analysis.)

What matters for choosing a supplement type is why a change is filed, because the change reason largely dictates the pathway — and therefore the timeline. The reason codes recorded in the PMA database fall into a few buckets, and each tends to route to a specific supplement type:

So manufacturing changes — the majority — are exactly the ones that qualify for the lighter 30-day/135-day pathways, while design changes push a supplement toward 180-day or real-time review. Keep that mapping in mind as you read the five types below.

The Five Supplement Types (and Two Adjacent Pathways)

FDA's framework, set out in 21 CFR 814.39 and elaborated in agency guidance, gives manufacturers several distinct vehicles depending on the nature and risk of the change.

180-Day Supplement

Used for major changes to a device's design, performance, principle of operation, control mechanism, or labeling — changes that can affect safety and effectiveness and may need new preclinical or limited clinical bridging data. The manufacturer submits, FDA reviews (with a 180-day review goal), and the change cannot be implemented until FDA approves. This is the workhorse for significant design evolution. In the database, design-and-material changes (the 21% bucket above) are the classic 180-day candidates. A representative example is STAAR Surgical's design-change supplement to the Visian Toric ICL (P030016).

Panel-Track Supplement

The most significant category, used for changes that require new clinical data and typically an advisory committee review — most commonly a new or expanded indication for use, a new patient population, or a new contraindication. Because it mirrors the rigor of an original PMA, panel-track supplements are rare relative to other types. A peer-reviewed Harvard analysis of cardiac implantable electronic devices (CIEDs, 1979–2012) found panel-track supplements accounted for just 0.3% of supplements, with 30-day notices (47%), 180-day (26%), and real-time (23%) making up the bulk.

Real-Time Supplement

For minor changes to device design, software, sterilization, or packaging — changes that may need new preclinical data but generally not new clinical data. FDA reviews these on an expedited "real-time" basis rather than the full 180-day cycle. Software and minor design iterations frequently land here.

30-Day Notice (and the 135-Day Supplement)

For changes to manufacturing procedures or methods of manufacture that affect safety and effectiveness. The manufacturer may distribute 30 days after FDA receives the notice, unless FDA objects or converts it. If FDA decides the supporting information is inadequate, it converts the notice into a 135-day supplement, which does require FDA review and approval. Given that over half of all supplements are process changes, this is the highest-volume pathway in practice. The database's "Express GMP Supplement" reason code (202 records) corresponds to this expedited manufacturing-change track.

Special PMA Supplement — "Changes Being Effected"

For labeling and manufacturing changes that enhance safety but do not affect effectiveness — for example, adding a new warning or correcting a manufacturing weakness. The manufacturer may implement the change immediately, on a temporary basis, while FDA reviews. It does not apply to design changes.

Two further categories sit alongside supplements rather than within them: manufacturing site-change supplements (when a QS inspection at the new site is more than two years old) and annual/periodic reports (changes that do not impact safety or effectiveness, reported on a schedule rather than through a supplement).

How to Choose: A Decision Guide

The selection logic flows from the type of change, the data required, and whether prior approval is needed before distribution:

1. Is it a manufacturing process or method change? Start with a 30-day notice; expect a possible 135-day conversion if FDA needs more data.
2. Is it a minor design, software, sterilization, or packaging change? A real-time supplement usually fits.
3. Is it a major design, component, material, or performance change? File a 180-day supplement and plan for preclinical (and possibly clinical) data.
4. Does it add or expand an indication, population, or contraindication needing new clinical data? File a panel-track supplement and prepare for committee review.
5. Is it a safety-enhancing labeling or manufacturing change with no effectiveness impact? Use the special "Changes Being Effected" supplement to implement while FDA reviews.
6. No safety or effectiveness impact? Report it in an annual report instead of a supplement.

Why Approval History Matters

A device's supplement history is a regulatory dossier in its own right. Because the average approved PMA accumulates dozens of supplements over its life, the current version of a device on the market may differ substantially from the originally approved model — and the only way to understand what changed, when, and through which pathway is to read the supplement chain. For competitive intelligence, due diligence ahead of an acquisition, or preparing a benchmark for a new submission, mapping a predicate or competitor's supplement history (change reasons, dates, and types) reveals where the real engineering and clinical investment has gone.

Key Takeaways

• 97% of PMA-database activity is supplements, not original approvals; the system exists to manage post-market change.
• Manufacturing changes (process, sterilization, site, supplier) drive ~61% of supplements and usually qualify for the 30-day/135-day track; design changes drive ~21% and push toward 180-day or real-time review.
• The supplement type sets your data burden, your FDA timeline, and whether you can ship before approval — so classify the change up front using 21 CFR 814.39.

Sources

• FDA, 21 CFR 814.39 — PMA supplements (eCFR).
• FDA guidance, "Modifications to Devices Subject to Premarket Approval (PMA) — The PMA Supplement Decision-Making Process."
• FDA guidance, "30-Day Notices, 135-Day Premarket Approval (PMA) Supplements, and Annual Reports."
• AdvaMed, "Premarket Approval — Regulatory Best Practices Guide."
• MedDeviceGuide analysis of the public FDA PMA approvals database (56,508 records, run date 2026-06-10); full record counts, applicant concentration, and year-over-year trends are in our PMA Class III landscape analysis. Data source: FDA PMA database.
• Rome BN, Kramer DB, Kesselheim AS. "FDA Approval of Cardiac Implantable Electronic Devices via Original and Supplement Premarket Approval Pathways, 1979–2012." JAMA. 2014;311(4):385. (Harvard analysis of CIED supplement-type distribution: 30-day 47%, 180-day 26%, real-time 23%, panel-track 0.3%.)